Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.59 |
| ▸ | AURKA | O14965 | 4/20 | 0.55 |
| ▸ | TTK | P33981 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.49 |
| ▸ | CLK2 | P49760 | 3/20 | 0.47 |
| ▸ | CLK3 | P49761 | 3/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | ITK | Q08881 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5387166 | 0.93 | AURKA (0.63) | MAP3K5AURKATTKMAPK8CLK2 | |
| SCHEMBL28517737 | 0.91 | MAP3K5 (0.73) | MAP3K5AURKATTKMAPK8LRRK2 | |
| SCHEMBL5379201 | 0.90 | MAP3K5 (0.57) | MAP3K5AURKATTKMAPK8LRRK2 | |
| SCHEMBL5381762 | 0.90 | MAP3K5 (0.60) | MAP3K5AURKATTKMAPK8CLK2 | |
| SCHEMBL5382244 | 0.90 | MAP3K5 (0.57) | MAP3K5AURKATTKMAPK8CLK2 | |
| SCHEMBL8252590 | 0.90 | CSNK1D (0.54) | MAP3K5AURKATTKMAPK8LRRK2 | |
| SCHEMBL5373348 | 0.89 | DYRK1A (0.53) | MAP3K5AURKATTKMAPK8CLK2 | |
| SCHEMBL28515624 | 0.89 | MAP3K5 (0.60) | MAP3K5AURKATTKMAPK8CSNK1D | |
| SCHEMBL5383348 | 0.89 | MAP3K5 (0.56) | MAP3K5AURKATTKMAPK8LRRK2 | |
| SCHEMBL6844212 | 0.88 | TTK (0.53) | MAP3K5AURKATTKMAPK8MAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050025795-A1 | Compounds, Compositions and methods for insect control | THE PROCTER & GAMBLE COMPANY (US) | 2005-02-03 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | MAP3K5 7/4885AURKA 3307/4885TTK 1198/4885 |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAP3K5 6/4885AURKA 1001/4885TTK 476/4885 |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | MAP3K5 20/4885AURKA 4517/4885TTK 354/4885 |
| US-20050025795-A1 | Compounds, Compositions and methods for insect control | PWWP2B, CUTA, WAPL | MAP3K5 4232/4885AURKA 3542/4885TTK 4493/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAP3K5 6/4885AURKA 1001/4885TTK 476/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | MAP3K5 32/4885AURKA 1439/4885TTK 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.